AstraZeneca's Farxiga scores landmark FDA nod in heart failure patients with or without diabetes

6th May 2020 Uncategorised 0

AstraZeneca has watched superstar SGLT2 diabetes med Farxiga nail trial after trial in highly coveted kidney and heart failure indications, with the FDA expediting reviews to back them up. The one thing AstraZeneca was missing? The agency taking Farxiga across the finish line. 

More: AstraZeneca's Farxiga scores landmark FDA nod in heart failure patients with or without diabetes
Source: fierce